...
首页> 外文期刊>Cell death & disease. >miR-375 is involved in Hippo pathway by targeting YAP1/TEAD4-CTGF axis in gastric carcinogenesis
【24h】

miR-375 is involved in Hippo pathway by targeting YAP1/TEAD4-CTGF axis in gastric carcinogenesis

机译:miR-375通过靶向胃癌发生中的YAP1 / TEAD4-CTGF轴参与Hippo途径

获取原文
   

获取外文期刊封面封底 >>

       

摘要

miR-375 is a tumor-suppressive microRNA (miRNA) in gastric cancer (GC). However, its molecular mechanism remains unclear. The aim of this study is to comprehensively investigate how miR-375 is involved in Hippo pathway by targeting multiple oncogenes. miR-375 expression in gastric cancer cell lines and primary GC was investigated by qRT-PCR. The regulation of YAP1, TEAD4, and CTGF expression by miR-375 was evaluated by qRT-PCR, western blot, and luciferase reporter assays, respectively. The functional roles of the related genes were examined by siRNA-mediated knockdown or ectopic expression assays. The clinical significance and expression correlation analysis of miR-375, YAP1, and CTGF were performed in primary GCs. TCGA cohort was also used to analyze the expression correlation of YAP1, TEAD4, CTGF, and miR-375 in primary GCs. miR-375 was down-regulated in GC due to promoter methylation and histone deacetylation. miR-375 downregulation was associated with unfavorable outcome and lymph node metastasis. Ectopic expression of miR-375 inhibited tumor growth in vitro and in vivo. Three components of Hippo pathway, YAP1, TEAD4 and CTGF, were revealed to be direct targets of miR-375. The expression of three genes showed a negative correlation with miR-375 expression and YAP1 re-expression partly abolished the tumor-suppressive effect of miR-375. Furthermore, CTGF was confirmed to be the key downstream of Hippo-YAP1 cascade and its knockdown phenocopied siYAP1 or miR-375 overexpression. YAP1 nuclear accumulation was?positively correlated with CTGF cytoplasmic expression in primary GC tissues. Verteporfin exerted an anti-oncogenic effect in GC cell lines by quenching CTGF expression through YAP1 degradation. In short, miR-375 was involved in the Hippo pathway by targeting YAP1-TEAD4-CTGF axis and enriched our knowledge on the miRNA dysregulation in gastric tumorigenesis.
机译:miR-375是胃癌(GC)中的肿瘤抑制性microRNA(miRNA)。但是,其分子机制仍不清楚。这项研究的目的是通过靶向多种致癌基因,全面研究miR-375如何参与河马途径。通过qRT-PCR研究miR-375在胃癌细胞系和原代GC中的表达。分别通过qRT-PCR,western blot和荧光素酶报告基因检测评估miR-375对YAP1,TEAD4和CTGF表达的调节。通过siRNA介导的敲除或异位表达测定法检查了相关基因的功能作用。在主要GC中进行了miR-375,YAP1和CTGF的临床意义和表达相关性分析。 TCGA队列还用于分析YAP1,TEAD4,CTGF和miR-375在主要GC中的表达相关性。由于启动子甲基化和组蛋白脱乙酰基作用,miR-375在GC中被下调。 miR-375的下调与不良结局和淋巴结转移有关。 miR-375的异位表达在体外和体内均可抑制肿瘤的生长。揭示了河马途径的三个成分,YAP1,TEAD4和CTGF,是miR-375的直接靶标。三个基因的表达与miR-375的表达呈负相关,YAP1的重新表达部分消除了miR-375的抑瘤作用。此外,CTGF被证实是Hippo-YAP1级联及其敲除表型siYAP1或miR-375过表达的关键下游。在原发性GC组织中,YAP1的核积累与CTGF的胞浆表达呈正相关。 Verteporfin通过YAP1降解终止CTGF表达,从而在GC细胞系中发挥抗癌作用。简而言之,miR-375通过靶向YAP1-TEAD4-CTGF轴参与了Hippo途径,丰富了我们在胃肿瘤发生中miRNA失调方面的知识。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号